• 1
    Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000; 343: 15451552.
  • 2
    Opelz G, Mickey MR, Terasaki PI. Influence of race on kidney transplant survival. Transplant Proc 1977; 9: 137142.
  • 3
    Gaston RS, Ayres I, Dooley LG, Diethelm AG. Racial equity in renal transplantation: The disparate impact of HLA-based allocation. J Am Med Assoc 1993; 270: 13521356.
  • 4
    Roberts JP, Wolfe RA, Bragg-Gresham JL et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. [see comment]. New England Journal of Medicine 2004; 350(6): 545551.
  • 5
    Pallet N, Thervet E, Alberti C et al. Kidney transplant in black recipients: Are African-Europeans different from African-Americans? Am J Transplant 2005; 5: 26822687.
  • 6
    Isaacs RB, Nock S, Spencer C et al. Racial disparities in renal transplant outcomes. Am J Kidney Dis 1999; 34: 706712.
  • 7
    Gaston RS, Danovitch GM, Adams PL et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003; 3(7):775785.
  • 8
    Hricik DE, Knauss TC, Bodziak KA et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003; 76(6): 938942.
  • 9
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 1999; 68(10): 15261532.
  • 10
    Neylan JF. Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997; 64: 12771282.
  • 11
    Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515523.
  • 12
    DeGeest S, Abraham I, Moons P et al. Late acute rejection and subclinical noncomliance with cyclosporine therapy in heart transplant recipients. J Heart Lung Transplantation 1998; 17: 854863.
  • 13
    De Geest S, Borgermans L, Gemoets H et al. Incidence, determinants and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59: 340347.
  • 14
    Oliver JD, Yuan CM, Welch PG, Swanson SJ, Reinmuth BW, Abbott KC. Renal allograft survival is independent of race in the US Military Health Care System (abstract). J Am Soc Nephrol 1999; 10: 741A.
  • 15
    Chakkera HA, O'Hare AM, Johansen KL et al. Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs. J Am Soc Nephrol 2005; 16: 269277.
  • 16
    Halloran PF. Call for revolution: A new approach to describing allograft deterioration. Am J Transplant 2002; 2(3): 195200.
  • 17
    Chandrakantan A, Kew C, Young C et al. Racial differences on cardiovascular risk profile and disease: A prevalence study (abstract). Am J Transplant 2005; 5(Suppl 11): 469.
  • 18
    Chaturvedi N, Bulpitt CJ, Leggetter S et al. Ethnic differences in vascular stiffness and relations to hypertensive target organ damage. Journal of Hypertension 2004; 22(9): 17311737.